$REPL
Replimune Group, Inc. Stock $repl

$repl Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-K Financial Statement

#000173795322000010 Filed on May 19, 2022

Income Statement

Concept	2022 Q1	2022	2021 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$10.25M	$38.77M	$5.960M
YoY Change	72.01%	67.11%	14.62%
% of Gross Profit
Research & Development	$21.22M	$79.55M	$15.71M
YoY Change	35.07%	40.16%	40.39%
% of Gross Profit
Depreciation & Amortization	$549.0K	$2.147M	$490.0K
YoY Change	12.04%	26.29%	44.12%
% of Gross Profit
Operating Expenses	$31.99M	$118.3M	$22.18M
YoY Change	44.22%	47.98%	35.33%
Operating Profit		-$118.3M
YoY Change		47.98%
Interest Expense	-$422.0K	-$1.833M	-$470.0K
YoY Change	-10.21%	-14.35%	-17.54%
% of Operating Profit
Other Income/Expense, Net	$714.0K	$278.0K	$1.150M
YoY Change	-37.91%	-130.38%	-0.86%
Pretax Income	-$31.70M	-$28.99M	-$21.50M
YoY Change	47.42%	27.27%	36.16%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$31.70M	-$118.0M	-$21.50M
YoY Change	47.42%	45.86%	36.16%
Net Earnings / Revenue
Basic Earnings Per Share		-$2.26
Diluted Earnings Per Share	-$603.3K	-$2.26	-$415.9K
COMMON SHARES
Basic Shares Outstanding	47.21M shares	52.21M shares
Diluted Shares Outstanding		52.21M shares

Balance Sheet

Concept	2022 Q1	2022	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$395.7M	$395.7M	$476.3M
YoY Change	-16.93%	-16.93%	182.5%
Cash & Equivalents	$105.9M	$105.9M	$182.5M
Short-Term Investments	$289.7M	$289.7M	$293.8M
Other Short-Term Assets	$5.267M	$5.267M	$4.500M
YoY Change	17.04%	17.04%	66.67%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$404.0M	$404.0M	$483.7M
YoY Change	-16.49%	-16.48%	177.54%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.933M	$55.58M	$7.442M
YoY Change	6.6%	-3.68%	-87.21%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.636M	$1.636M	$1.600M
YoY Change	2.25%	2.25%	0.0%
Total Long-Term Assets	$57.22M	$57.22M	$59.35M
YoY Change	-3.6%	-3.68%	-0.75%
TOTAL ASSETS
Total Short-Term Assets	$404.0M	$404.0M	$483.7M
Total Long-Term Assets	$57.22M	$57.22M	$59.35M
Total Assets	$461.2M	$461.2M	$543.1M
YoY Change	-15.08%	-15.08%	131.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.732M	$3.732M	$2.355M
YoY Change	58.47%	55.5%	-30.74%
Accrued Expenses	$13.14M	$13.14M	$9.200M
YoY Change	42.85%	42.85%	61.4%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.562M	$2.562M	$2.500M
YoY Change	2.48%	2.48%	4.17%
Total Short-Term Liabilities	$20.76M	$20.76M	$14.55M
YoY Change	42.68%	43.14%	22.24%
LONG-TERM LIABILITIES
Long-Term Debt	$24.41M	$24.41M	$24.70M
YoY Change	-1.19%	-1.19%	-29.02%
Other Long-Term Liabilities	$4.801M	$4.801M	$5.100M
YoY Change	-5.86%	-5.86%	37.84%
Total Long-Term Liabilities	$29.21M	$29.21M	$29.80M
YoY Change	-1.99%	-1.99%	-22.6%
TOTAL LIABILITIES
Total Short-Term Liabilities	$20.76M	$20.76M	$14.55M
Total Long-Term Liabilities	$29.21M	$29.21M	$29.80M
Total Liabilities	$49.96M	$49.96M	$44.37M
YoY Change	12.61%	12.53%	-11.96%
SHAREHOLDERS EQUITY
Retained Earnings	-$311.2M		-$193.2M
YoY Change	61.11%
Common Stock	$47.00K		$47.00K
YoY Change	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$411.2M	$411.2M	$498.7M
YoY Change
Total Liabilities & Shareholders Equity	$461.2M	$461.2M	$543.1M
YoY Change	-15.08%	-15.08%	131.99%

Cashflow Statement

Concept	2022 Q1	2022	2021 Q1
OPERATING ACTIVITIES
Net Income	-$31.70M	-$118.0M	-$21.50M
YoY Change	47.42%	45.86%	36.16%
Depreciation, Depletion And Amortization	$549.0K	$2.147M	$490.0K
YoY Change	12.04%	26.29%	44.12%
Cash From Operating Activities	-$22.56M	-$82.18M	-$16.13M
YoY Change	39.85%	33.87%	43.25%
INVESTING ACTIVITIES
Capital Expenditures	-$1.152M	$2.336M	-$770.0K
YoY Change	49.61%	-2.34%	-42.54%
Acquisitions
YoY Change
Other Investing Activities	-$3.174M	$530.0K	-$125.5M
YoY Change	-97.47%	-100.28%	-1467.1%
Cash From Investing Activities	-$4.326M	-$1.806M	-$126.3M
YoY Change	-96.57%	-99.04%	-1710.71%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00
YoY Change		-100.0%
Debt Paid & Issued, Net		$0.00
YoY Change		-100.0%
Cash From Financing Activities	359.0K	$6.598M	780.0K
YoY Change	-53.97%	-98.23%	1850.0%
NET CHANGE
Cash From Operating Activities	-22.56M	-$82.18M	-16.13M
Cash From Investing Activities	-4.326M	-$1.806M	-126.3M
Cash From Financing Activities	359.0K	$6.598M	780.0K
Net Change In Cash	-26.52M	-$76.57M	-141.6M
YoY Change	-81.27%	-162.24%	4090.24%
FREE CASH FLOW
Cash From Operating Activities	-$22.56M	-$82.18M	-$16.13M
Capital Expenditures	-$1.152M	$2.336M	-$770.0K
Free Cash Flow	-$21.41M	-$84.52M	-$15.36M
YoY Change	39.36%	32.51%	54.84%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001737953
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-38596
CY2022	dei	Entity Registrant Name EntityRegistrantName	REPLIMUNE GROUP, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-2082553
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	500 Unicorn Park Drive
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Woburn
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	01801
CY2022	dei	City Area Code CityAreaCode	781
CY2022	dei	Local Phone Number LocalPhoneNumber	222-9600
CY2022	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2022	dei	Trading Symbol TradingSymbol	REPL
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Auditor Location AuditorLocation	Boston, Massachusetts
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2021Q3	dei	Entity Public Float EntityPublicFloat	620300000	USD
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	49069995	shares
CY2022	dei	Auditor Firm AuditorFirmId	238
CY2022	dei	Auditor Name AuditorName	PricewaterhouseCoopers LLP
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	105948000	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	182518000	USD
CY2022Q1	us-gaap	Short Term Investments ShortTermInvestments	289707000	USD
CY2021Q1	us-gaap	Short Term Investments ShortTermInvestments	293784000	USD
CY2022Q1	repl	Research And Development Incentives Receivable Current ResearchAndDevelopmentIncentivesReceivableCurrent	3055000	USD
CY2021Q1	repl	Research And Development Incentives Receivable Current ResearchAndDevelopmentIncentivesReceivableCurrent	2953000	USD
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5267000	USD
CY2021Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4492000	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	403977000	USD
CY2021Q1	us-gaap	Assets Current AssetsCurrent	483747000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7933000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7442000	USD
CY2022Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1636000	USD
CY2021Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1636000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5552000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5751000	USD
CY2022Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	42094000	USD
CY2021Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	44522000	USD
CY2022Q1	us-gaap	Assets Assets	461192000	USD
CY2021Q1	us-gaap	Assets Assets	543098000	USD
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	3732000	USD
CY2021Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2355000	USD
CY2022Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	13392000	USD
CY2021Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	8735000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1070000	USD
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	970000	USD
CY2022Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2562000	USD
CY2021Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2487000	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	20756000	USD
CY2021Q1	us-gaap	Liabilities Current LiabilitiesCurrent	14547000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4801000	USD
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5078000	USD
CY2022Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	24406000	USD
CY2021Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	24745000	USD
CY2022Q1	us-gaap	Liabilities Liabilities	49963000	USD
CY2021Q1	us-gaap	Liabilities Liabilities	44370000	USD
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	47338660	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	47338660	shares
CY2021Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	46566481	shares
CY2021Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	46566481	shares
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	47000	USD
CY2021Q1	us-gaap	Common Stock Value CommonStockValue	47000	USD
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	723359000	USD
CY2021Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	692243000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-311204000	USD
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2100000	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-193168000	USD
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-973000	USD
CY2021Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-394000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	411229000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	498728000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	461192000	USD
CY2021Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	543098000	USD
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	79545000	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	56754000	USD
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	38769000	USD
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	23201000	USD
CY2022	us-gaap	Operating Expenses OperatingExpenses	118314000	USD
CY2021	us-gaap	Operating Expenses OperatingExpenses	79955000	USD
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-118314000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-79955000	USD
CY2022	repl	Research And Development Incentives Income ResearchAndDevelopmentIncentivesIncome	3170000	USD
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1059000	USD
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-665000	USD
CY2021	repl	Research And Development Incentives Income ResearchAndDevelopmentIncentivesIncome	2807000	USD
CY2022	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	390000	USD
CY2021	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	916000	USD
CY2022	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	2223000	USD
CY2021	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	2242000	USD
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt	0	USD
CY2021	us-gaap	Interest Expense Debt InterestExpenseDebt	818000	USD
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-913000	USD
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	278000	USD
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-915000	USD
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-118036000	USD
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-80870000	USD
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.26
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.26
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.75
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.75
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	52212269	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	52212269	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	46248969	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	46248969	shares
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-118036000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-80870000	USD
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	748000	USD
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	866000	USD
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	0	USD
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-1327000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-278000	USD
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-118615000	USD
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-80282000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	183718000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	91650000	USD
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	286107000	USD
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	866000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-278000	USD
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5745000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11790000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-80870000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	498728000	USD
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	748000	USD
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-1327000	USD
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6862000	USD
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	24254000	USD
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-118036000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	411229000	USD
CY2022	us-gaap	Profit Loss ProfitLoss	-118036000	USD
CY2021	us-gaap	Profit Loss ProfitLoss	-80870000	USD
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	24254000	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	11790000	USD
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2147000	USD
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1711000	USD
CY2022	repl	Net Amortization Of Premiums And Discounts On Short Term Investments NetAmortizationOfPremiumsAndDiscountsOnShortTermInvestments	-2220000	USD
CY2021	repl	Net Amortization Of Premiums And Discounts On Short Term Investments NetAmortizationOfPremiumsAndDiscountsOnShortTermInvestments	-1376000	USD
CY2022	us-gaap	Paid In Kind Interest PaidInKindInterest	0	USD
CY2021	us-gaap	Paid In Kind Interest PaidInKindInterest	181000	USD
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-913000	USD
CY2022	repl	Increase Decrease In Research And Development Incentives Receivable IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable	247000	USD
CY2021	repl	Increase Decrease In Research And Development Incentives Receivable IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable	-325000	USD
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	815000	USD
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1707000	USD
CY2022	repl	Increase Decrease Operating Lease Right Of Use Asset IncreaseDecreaseOperatingLeaseRightOfUseAsset	-99000	USD
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-82180000	USD
CY2021	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	206050000	USD
CY2021	repl	Increase Decrease Operating Lease Right Of Use Asset IncreaseDecreaseOperatingLeaseRightOfUseAsset	-447000	USD
CY2022	repl	Increase Decrease Finance Lease Right Of Use Asset IncreaseDecreaseFinanceLeaseRightOfUseAsset	-2428000	USD
CY2021	repl	Increase Decrease Finance Lease Right Of Use Asset IncreaseDecreaseFinanceLeaseRightOfUseAsset	-2403000	USD
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1118000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1031000	USD
CY2022	repl	Increase Decrease In Accrued Expenses And Other Current Liabilities IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities	4725000	USD
CY2021	repl	Increase Decrease In Accrued Expenses And Other Current Liabilities IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities	3413000	USD
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-73000	USD
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-340000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-61389000	USD
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2336000	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2392000	USD
CY2022	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	255720000	USD
CY2021	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	392434000	USD
CY2022	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	256250000	USD
CY2021	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	91650000	USD
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6862000	USD
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5745000	USD
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6598000	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	372462000	USD
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1806000	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-188776000	USD
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	286107000	USD
CY2022	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0	USD
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	100000	USD
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	264000	USD
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	145000	USD
CY2022	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
CY2021	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	10000000	USD
CY2022	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	0	USD
CY2021	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	795000	USD
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	818000	USD
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	721000	USD
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-76570000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	123018000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	184154000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	61136000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	107584000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	184154000	USD
CY2022	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2021	us-gaap	Interest Paid Net InterestPaidNet	636000	USD
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	55000	USD
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	415000	USD
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	98000	USD
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	363000	USD
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1580000	USD
CY2022	us-gaap	Nature Of Operations NatureOfOperations	Nature of the business<div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Replimune Group, Inc. (the “Company”) is a clinical-stage biotechnology company focused on the development of oncolytic immunotherapies to treat cancer. Replimune Group, Inc., whose predecessor was founded in 2015, is the parent company of its wholly owned, direct and indirect subsidiaries: Replimune Limited (“Replimune UK”); Replimune, Inc. (“Replimune US”); Replimune Securities Corporation; and Replimune (Ireland) Limited.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance and reporting capabilities. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of presentation</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. The Company has incurred recurring losses since its inception, including net losses of $118.0 million and $80.9 million for the years ended March 31, 2022 and 2021, respectively. In addition, as of March 31, 2022, the Company had an accumulated deficit of $311.2 million. The Company expects to continue to generate operating losses for the foreseeable future. As of the issuance date of these consolidated financial statements, the Company expects that its cash and cash equivalents and short-term investments will be sufficient to fund its operating expenses and capital expenditure requirements through at least 12 months from the issuance of the consolidated financial statements.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact of COVID-19 </span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, a novel strain of coronavirus, which causes the disease known as COVID-19, was reported to have surfaced in Wuhan, China. Since then, COVID-19 coronavirus has spread globally. In March 2020, the World Health Organization declared the COVID-19 outbreak a pandemic and the U.S. government imposed travel restrictions on travel between the United States, Europe and certain other countries. The impact of this pandemic has been, and will likely continue to be, extensive in many aspects of society, which has resulted, and will likely continue to result, in significant disruption to the global economy as well as businesses and capital markets around the world.</span></div>In response to public health directives and orders and to help minimize the risk of the virus to employees, the Company has taken precautionary measures including establishing and maintaining an internal COVID-19 task force to ensure timely communication and decision-making in response to COVID-19, establishing work-from home policies and return-to-office policies as well as other measures to respond and adapt to the COVID-19 impact. For those employees working from our offices, laboratories and manufacturing facilities, we have implemented stringent safety measures designed to comply with applicable federal, state and local guidelines instituted in response to the COVID-19 pandemic and we continue to examine our protocols as the pandemic and health guidance evolves. The Company has taken these and other precautionary steps while maintaining business continuity in order to continue to progress its programs. While there has been no prolonged material disruption to the Company’s business to date, the impact of the virus, including work-from-home policies, may negatively impact productivity, disrupt the Company’s business, and delay its preclinical research and clinical trial activities and its development program timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on the Company’s ability to conduct its business in the ordinary course. Other impacts to the Company’s business may include disruptions of its suppliers or material supplies and disruptions or restrictions on its employees’ ability to travel. Any prolonged material disruption to the Company’s employees, suppliers or supply could adversely impact the Company’s preclinical research and clinical trial activities, financial condition and results of operations, including its ability to obtain financing.
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-118000000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-80900000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-311200000	USD
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual for research and development expenses and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including, expenses, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19. We have made estimates of the impact of COVID-19 within our financial statements and there may be changes to those estimates in future periods.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimates are periodically reviewed in light of reasonable changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates or assumptions.</span></div>
CY2022Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	75117000	USD
CY2021Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	150734000	USD
CY2021	repl	Research And Development Incentives Income ResearchAndDevelopmentIncentivesIncome	2807000	USD
CY2022Q1	repl	Research And Development Incentives Receivable Current ResearchAndDevelopmentIncentivesReceivableCurrent	3055000	USD
CY2022	repl	Research And Development Incentives Income ResearchAndDevelopmentIncentivesIncome	3170000	USD
CY2021Q1	repl	Research And Development Incentives Receivable Current ResearchAndDevelopmentIncentivesReceivableCurrent	2953000	USD
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	748000	USD
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-1327000	USD
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	866000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-278000	USD
CY2022	repl	Minimum Percentage Of Income Tax Benefit Realized Upon Ultimate Settlement MinimumPercentageOfIncomeTaxBenefitRealizedUponUltimateSettlement	0.50
CY2022Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4795000	USD
CY2021Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2648000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7933000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7442000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	12728000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	10090000	USD
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1700000	USD
CY2022Q1	repl	Accrued Research And Development Costs AccruedResearchAndDevelopmentCosts	5882000	USD
CY2021Q1	repl	Accrued Research And Development Costs AccruedResearchAndDevelopmentCosts	3862000	USD
CY2022Q1	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	5569000	USD
CY2021Q1	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	3952000	USD
CY2022Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	621000	USD
CY2021Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	407000	USD
CY2022Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1320000	USD
CY2021Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	514000	USD
CY2022Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	13392000	USD
CY2021Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	8735000	USD
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	85598000	USD
CY2020Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	107782000	USD
CY2020Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	269975000	USD
CY2022Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	5284238	shares
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	24254000	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	11790000	USD
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	24254000	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	11790000	USD
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	125000	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6460184	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	13.26
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y11M12D
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	116193000	USD
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1573862	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	31.29
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	768186	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	8.93
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	751526	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	24.93
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6514334	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	16.78
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y3M3D
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	30358000	USD
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2698708	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	8.38
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y9M14D
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	59717000	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3645749	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	10.85
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y3M21D
CY2022Q1	repl	Operating And Finance Lease Liability Payments Due After Year Five OperatingAndFinanceLeaseLiabilityPaymentsDueAfterYearFive	41000000	USD
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	52212269	shares
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	24875000	USD
CY2022Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	37900000	USD
CY2022	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y6M3D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	21.40
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	12.03
CY2022	repl	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue	16200000	USD
CY2021	repl	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue	24900000	USD
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-118036000	USD
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-80870000	USD
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	52212269	shares
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	8375000	USD
CY2022Q1	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	51623000	USD
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	46248969	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	46248969	shares
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.26
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.26
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.75
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.75
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7011678	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6973503	shares
CY2021Q4	repl	Lessee Operating Lease Rentable Area LesseeOperatingLeaseRentableArea	2951	sqft
CY2021Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P5Y
CY2021Q4	repl	Operating Lease Annual Lease Payments OperatingLeaseAnnualLeasePayments	100000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	400000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	400000	USD
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	2428000	USD
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	2428000	USD
CY2022	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	2223000	USD
CY2021	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	2242000	USD
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	1003000	USD
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	948000	USD
CY2022	us-gaap	Lease Cost LeaseCost	5654000	USD
CY2021	us-gaap	Lease Cost LeaseCost	5618000	USD
CY2022	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	2223000	USD
CY2021	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	2242000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1070000	USD
CY2022Q1	repl	Operating And Finance Lease Liability Payments Due OperatingAndFinanceLeaseLiabilityPaymentsDue	59998000	USD
CY2022Q1	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	2562000	USD
CY2022Q1	repl	Operating And Finance Lease Liability Payments Due Next Twelve Months OperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths	3632000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1079000	USD
CY2022Q1	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	2639000	USD
CY2022Q1	repl	Operating And Finance Lease Liability Payments Due Year Two OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo	3718000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1088000	USD
CY2022Q1	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	2718000	USD
CY2022Q1	repl	Operating And Finance Lease Liability Payments Due Year Three OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree	3806000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1098000	USD
CY2022Q1	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	2799000	USD
CY2022Q1	repl	Operating Finance Lease Liability Payments Due Year Four OperatingFinanceLeaseLiabilityPaymentsDueYearFour	3897000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1062000	USD
CY2022Q1	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	2883000	USD
CY2022Q1	repl	Operating And Finance Lease Liability Payments Due Year Five OperatingAndFinanceLeaseLiabilityPaymentsDueYearFive	3945000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	2978000	USD
CY2022Q1	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive	38022000	USD
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0	USD
CY2022Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y8M12D
CY2022Q1	us-gaap	Finance Lease Liability FinanceLeaseLiability	26968000	USD
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	5871000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2504000	USD
CY2022Q1	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	24655000	USD
CY2022Q1	repl	Operating And Finance Lease Liability Undiscounted Excess Amount OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount	27159000	USD
CY2022Q1	repl	Operating And Finance Lease Liability OperatingAndFinanceLeaseLiability	32839000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5552000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5751000	USD
CY2022Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	42094000	USD
CY2021Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	44522000	USD
CY2022Q1	repl	Lease Right Of Use Asset LeaseRightOfUseAsset	47646000	USD
CY2021Q1	repl	Lease Right Of Use Asset LeaseRightOfUseAsset	50273000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1070000	USD
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	970000	USD
CY2022Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2562000	USD
CY2021Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2487000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4801000	USD
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5078000	USD
CY2022Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	24406000	USD
CY2021Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	24745000	USD
CY2022Q1	repl	Lease Liability LeaseLiability	32839000	USD
CY2021Q1	repl	Lease Liability LeaseLiability	33280000	USD
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	968000	USD
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	823000	USD
CY2022	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	2223000	USD
CY2021	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	2240000	USD
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	264000	USD
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	145000	USD
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	363000	USD
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1580000	USD
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0	USD
CY2021	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-80870000	USD
CY2021Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y10M24D
CY2022Q1	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P17Y3M18D
CY2021Q1	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P18Y3M18D
CY2022Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.101
CY2021Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.098
CY2022Q1	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.083
CY2021Q1	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.083
CY2022Q1	us-gaap	Purchase Commitment Remaining Minimum Amount Committed PurchaseCommitmentRemainingMinimumAmountCommitted	1951000	USD
CY2021Q1	us-gaap	Purchase Commitment Remaining Minimum Amount Committed PurchaseCommitmentRemainingMinimumAmountCommitted	1651000	USD
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-58095000	USD
CY2022	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-118036000	USD
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-28985000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-22775000	USD
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-89051000	USD
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.003
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.024
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.008
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	-0.010
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	-0.019
CY2022	repl	Effective Income Tax Rate Reconciliation Return To Provision Percent EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent	0.002
CY2021	repl	Effective Income Tax Rate Reconciliation Return To Provision Percent EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent	-0.000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.021
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.039
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.015
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.106
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.311
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.259
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.006
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.003
CY2022Q1	repl	Deferred Tax Assets Operating Loss Carryforwards Federal Net DeferredTaxAssetsOperatingLossCarryforwardsFederalNet	9827000	USD
CY2021Q1	repl	Deferred Tax Assets Operating Loss Carryforwards Federal Net DeferredTaxAssetsOperatingLossCarryforwardsFederalNet	7083000	USD
CY2022Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	48588000	USD
CY2021Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	22195000	USD
CY2022Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	2697000	USD
CY2021Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	2358000	USD
CY2022Q1	repl	Research And Development Credits ResearchAndDevelopmentCredits	1000000	USD
CY2021Q1	repl	Research And Development Credits ResearchAndDevelopmentCredits	787000	USD
CY2022Q1	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	4367000	USD
CY2021Q1	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	5068000	USD
CY2022Q1	repl	Deferred Tax Assets Capitalization Of Start Up Cost DeferredTaxAssetsCapitalizationOfStartUpCost	1286000	USD
CY2021Q1	repl	Deferred Tax Assets Capitalization Of Start Up Cost DeferredTaxAssetsCapitalizationOfStartUpCost	1597000	USD
CY2022Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	8922000	USD
CY2021Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4838000	USD
CY2022Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	1452000	USD
CY2021Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	739000	USD
CY2022Q1	repl	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	7309000	USD
CY2021Q1	repl	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	8462000	USD
CY2022Q1	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	310000	USD
CY2021Q1	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	0	USD
CY2022Q1	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	85758000	USD
CY2021Q1	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	53127000	USD
CY2022Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	74892000	USD
CY2021Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	40028000	USD
CY2022Q1	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	10866000	USD
CY2021Q1	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	13099000	USD
CY2022Q1	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	10866000	USD
CY2021Q1	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	13090000	USD
CY2022Q1	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0	USD
CY2021Q1	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	9000	USD
CY2022Q1	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	10866000	USD
CY2021Q1	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	13099000	USD
CY2022Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	74892000	USD
CY2021Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	40028000	USD
CY2022Q1	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0	USD
CY2021Q1	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0	USD
CY2021Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	40028000	USD
CY2020Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	17329000	USD
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	36679000	USD
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	22624000	USD
CY2022	repl	Valuation Allowance Deferred Tax Asset Increase Recorded To Income Tax Provision For Equity Amount ValuationAllowanceDeferredTaxAssetIncreaseRecordedToIncomeTaxProvisionForEquityAmount	-1815000	USD
CY2021	repl	Valuation Allowance Deferred Tax Asset Increase Recorded To Income Tax Provision For Equity Amount ValuationAllowanceDeferredTaxAssetIncreaseRecordedToIncomeTaxProvisionForEquityAmount	76000	USD
CY2022Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2021Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2022Q1	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2021Q1	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2022	repl	Number Of Operating Geographic Regions NumberOfOperatingGeographicRegions	2	region
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7933000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7442000	USD

Files In Submission

Name	View Source	Status
0001737953-22-000010-index-headers.html	Edgar Link	pending
0001737953-22-000010-index.html	Edgar Link	pending
0001737953-22-000010.txt	Edgar Link	pending
0001737953-22-000010-xbrl.zip	Edgar Link	pending
exhibit1027105800-01_x1246.htm	Edgar Link	pending
exhibit211_replimunexsubsi.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
repl-20220331.htm	Edgar Link	pending
repl-20220331.xsd	Edgar Link	pending
repl-20220331x10kxex312.htm	Edgar Link	pending
repl-20220331x10kxex321.htm	Edgar Link	pending
repl-20220331x10kxex322.htm	Edgar Link	pending
repl-20220331x10kxex43.htm	Edgar Link	pending
repl-20220331x10kxexx311.htm	Edgar Link	pending
repl-20220331_cal.xml	Edgar Link	unprocessable
repl-20220331_def.xml	Edgar Link	unprocessable
repl-20220331_g1.jpg	Edgar Link	pending
repl-20220331_htm.xml	Edgar Link	completed
repl-20220331_lab.xml	Edgar Link	unprocessable
repl-20220331_pre.xml	Edgar Link	unprocessable
replimunefy22consentforex2.htm	Edgar Link	pending
replimunegroupinc-2018omni.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$REPL
Replimune Group, Inc. Stock $repl

2022 Q1 Form 10-K Financial Statement

#000173795322000010 Filed on May 19, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$REPL Replimune Group, Inc. Stock $repl

2022 Q1 Form 10-K Financial Statement

#000173795322000010 Filed on May 19, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$REPL
Replimune Group, Inc. Stock $repl